Stockscreener 앱 받기
33.19
0.76%
0.25
시간 외 거래:
33.19
전일 마감가:
$32.94
열려 있는:
$32.56
하루 거래량:
1.18M
Relative Volume:
0.52
시가총액:
$3.87B
수익:
-
순이익/손실:
$-472.34M
주가수익비율:
-8.0055
EPS:
-4.1459
순현금흐름:
$-340.33M
1주 성능:
-3.12%
1개월 성능:
-12.59%
6개월 성능:
+14.45%
1년 성능:
-17.52%
1일 변동 폭
$32.33
$33.28
1주일 범위
$32.33
$34.85
52주 변동 폭
$22.96
$43.15
Viking Therapeutics Inc Stock (VKTX) Company Profile
명칭
Viking Therapeutics Inc
전화
858-704-4660
주소
9920 PACIFIC HEIGHTS BLVD, SUITE 350, SAN DIEGO, CA
Compare VKTX vs VRTX, REGN, ARGX, RVMD, ONC
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
VKTX
Viking Therapeutics Inc
|
33.19 | 3.97B | 0 | -472.34M | -340.33M | -4.1459 |
VRTX
Vertex Pharmaceuticals Inc
|
505.75 | 133.25B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
803.48 | 82.16B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
851.29 | 54.80B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
203.71 | 43.99B | 742.00K | -1.37B | -1.07B | -7.0731 |
ONC
Beone Medicines Ltd Adr
|
347.48 | 40.62B | 5.76B | 514.49M | 1.10B | 4.4813 |
Viking Therapeutics Inc Stock (VKTX) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-03-26 | 개시 | Wolfe Research | Peer Perform |
| 2025-10-29 | 개시 | Canaccord Genuity | Buy |
| 2025-04-29 | 개시 | Cantor Fitzgerald | Overweight |
| 2025-04-08 | 개시 | Goldman | Neutral |
| 2025-02-13 | 개시 | Scotiabank | Sector Outperform |
| 2025-02-07 | 개시 | Citigroup | Neutral |
| 2024-12-02 | 개시 | Piper Sandler | Overweight |
| 2024-11-22 | 개시 | B. Riley Securities | Buy |
| 2024-11-04 | 재확인 | H.C. Wainwright | Buy |
| 2024-09-11 | 개시 | JP Morgan | Overweight |
| 2024-06-27 | 개시 | Morgan Stanley | Overweight |
| 2024-05-16 | 업그레이드 | Raymond James | Outperform → Strong Buy |
| 2024-03-26 | 재확인 | Oppenheimer | Outperform |
| 2024-03-07 | 개시 | Jefferies | Buy |
| 2024-02-28 | 재확인 | Oppenheimer | Outperform |
| 2023-05-31 | 재개 | ROTH MKM | Buy |
| 2023-03-28 | 재확인 | Maxim Group | Buy |
| 2023-03-17 | 개시 | Stifel | Buy |
| 2021-07-29 | 재개 | BTIG Research | Buy |
| 2021-05-25 | 다운그레이드 | Raymond James | Strong Buy → Outperform |
| 2020-06-05 | 개시 | BMO Capital Markets | Outperform |
| 2020-05-05 | 개시 | Chardan Capital Markets | Buy |
| 2020-05-01 | 개시 | BTIG Research | Buy |
| 2019-07-16 | 개시 | Oppenheimer | Outperform |
| 2019-06-25 | 개시 | Stifel | Buy |
| 2019-03-29 | 업그레이드 | SVB Leerink | Mkt Perform → Outperform |
| 2019-03-14 | 재확인 | Maxim Group | Buy |
| 2019-02-22 | 개시 | SVB Leerink | Mkt Perform |
| 2018-12-12 | 개시 | B. Riley FBR | Buy |
| 2018-11-19 | 업그레이드 | Raymond James | Outperform → Strong Buy |
| 2018-09-18 | 재확인 | H.C. Wainwright | Buy |
| 2018-09-18 | 재확인 | Maxim Group | Buy |
| 2018-09-18 | 재확인 | Raymond James | Outperform |
| 2018-07-20 | 개시 | SunTrust | Buy |
| 2018-06-28 | 개시 | Raymond James | Outperform |
| 2018-06-01 | 재확인 | Laidlaw | Buy |
| 2018-05-31 | 재확인 | Maxim Group | Buy |
| 2018-03-26 | 재개 | H.C. Wainwright | Buy |
| 2017-11-28 | 재확인 | Maxim Group | Buy |
| 2017-11-21 | 개시 | ROTH Capital | Buy |
모두보기
Viking Therapeutics Inc 주식(VKTX)의 최신 뉴스
Viking Therapeutics, Inc. (VKTX) Stock Price, News, Quote & History - finance.yahoo.com
VKTX Eyes Worst Week Since November As Trial Data Looms — Wall Street Still Sees 200% Upside - Stocktwits
VKTX Stock Clocks Best Day In Nearly 3 Months On Obesity Pipeline Optimism, Buyout Speculation - Stocktwits
Cornerstone Capital Inc. Takes $3.33 Million Position in Viking Therapeutics, Inc. $VKTX - marketbeat.com
Viking Therapeutics Inc (VKTX) News, Articles, Events & Latest Updates - Stocktwits
VKTX Stock Has Nearly 300% Wall Street Upside — Is Viking’s Oral Obesity Pill The Next Novo Nordisk-Style Breakout? - Stocktwits
VKTX Stock Rallies After Hours On Optimism Around Company’s Obesity Pipeline - Stocktwits
A New GLP-1 Challenger? Early Data Shows Viking's New Obesity Drug Tops Novo Rival - Stocktwits
(VKTX) Price Dynamics and Execution-Aware Positioning - Stock Traders Daily
LLY, NVO Stocks Led May’s GLP-1 Rally — But This Smaller ‘Differentiated Player’ Got A Bold 160% Upside Call - Stocktwits
VKTX Stock Outpaces LLY, ALT Ahead Of Earnings – Retail Eyes Breakout Ahead - Stocktwits
symbol__ Stock Quote Price and Forecast - CNN
Viking Therapeutics Inc (VKTX) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Viking Therapeutics Moves Closer To Challenging Ozempic With Phase 3 Trial Progress - Stocktwits
Viking Therapeutics Declined in July, and why its Long-Term Prospects are Undiminished - AOL.com
VKTX Maintained by JP Morgan -- Price Target Lowered to $65 - GuruFocus
JPMorgan Chase & Co. Issues Pessimistic Forecast for Viking Therapeutics (NASDAQ:VKTX) Stock Price - marketbeat.com
Viking Therapeutics (VKTX) Short Interest & Short Float | Updated Aug 2026 - marketbeat.com
Viking Therapeutics Inc (VKTX) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Better GLP-1 Stock to Buy: Eli Lilly or Viking Therapeutics? - Yahoo Finance
Royal Bank of Canada Decreases Stock Position in Viking Therapeutics, Inc. $VKTX - marketbeat.com
Viking Therapeutics, Inc. $VKTX Stake Raised by Dimensional Fund Advisors LP - marketbeat.com
Viking Therapeutics Inc (VKTX) Stock News Today - TradingKey
Viking Therapeutics: Mysterious GLP-1 Player With A Key Catalyst Due Q3 (Q2 Earnings Overview) - Seeking Alpha
First Trust Advisors LP Acquires Shares of 105,570 Viking Therapeutics, Inc. $VKTX - MarketBeat
Viking Therapeutics, Inc. (NASDAQ:VKTX) Given Consensus Recommendation of "Moderate Buy" by Brokerages - MarketBeat
Viking Therapeutics, Inc. (VKTX) - DirectorsTalk Interviews
Viking Therapeutics, Inc. (VKTX) options chain - Yahoo Finance Australia
Viking Therapeutics Stock Moves Lower: What's Going On? - TradingView
VKTX Stock Lags GLP-1 Peers In July — But Viking CEO Says Its Obesity Drug Could Offer What Rivals Can’t - Stocktwits
Viking's Obesity Treatments Advance as New Data, Trials Loom, Oppenheimer Says - moomoo.com
Viking Therapeutics reports Q2 loss, R&D spend drives net loss; cash $502M at June 30, 2026 - TradingView
Viking Therapeutics Q2 Earnings Call Highlights - TradingView
Viking Therapeutics (VKTX) Q2 Earnings Preview: Market Pricing i - GuruFocus
Can These 5 Biotech Stocks Beat Wall Street's Q2 Estimates? - Yahoo Finance
Is Viking Therapeutics (VKTX) a Buy as Wall Street Analysts Look Optimistic? - Yahoo Finance
Viking Therapeutics, Inc. (VKTX) Stock Analysis: Exploring a 165% Potential Upside in the Biotech Sector - DirectorsTalk Interviews
VKTX|Viking Therapeutics Inc|Price:34.880|Chg%:+0.090 - TradingKey
Viking Therapeutics Inc expected to post a loss of $1.25 a shareEarnings Preview - TradingView
Insiders At Viking Therapeutics Sold US$15m In Stock, Alluding To Potential Weakness - Moomoo
Viking Therapeutics (NASDAQ:VKTX) Stock in Focus Ahead of Cash-Burn Scrutiny, Earnings Set for July 29 - TechStock²
VKTX Stock Rises After-Hours: CNBC Flags Viking As Likely Buyout Target This Year As Big Pharma Hunts Next GLP-1 Winner - Stocktwits
Viking Therapeutics, Inc. Revenue Breakdown – DUS:1VT - TradingView
Viking Therapeutics Inc (VKTX) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Viking Therapeutics Inc (VKTX) Cash Flow - TradingKey
TradingKey - TradingKey
Viking Therapeutics Inc (VKTX) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Viking Therapeutics Inc (VKTX) Valuation: PE, PB & Fair Value Analysis - TradingKey
VKTX Stock Draws Fresh Attention Ahead Of Earnings: Wall Street Sees Over 170% Upside As GLP-1 Race Burns Hot - Stocktwits
Viking Therapeutics Inc (VKTX) Institutional Confidence - TradingKey
VKTX|Viking Therapeutics Inc|Price:34.770|Chg%:-0.620 - TradingKey
Viking Therapeutics Inc (VKTX) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.52%
0.07%
자본화:
|
볼륨(24시간):